InMode Ltd. (NASDAQ:INMD) Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its position in InMode Ltd. (NASDAQ:INMD) by 6.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 44,196 shares of the healthcare company’s stock after selling 3,033 shares during the period. American Century Companies Inc. owned 0.05% of InMode worth $806,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DDD Partners LLC grew its position in InMode by 19.4% in the 2nd quarter. DDD Partners LLC now owns 1,266,678 shares of the healthcare company’s stock valued at $23,104,000 after acquiring an additional 205,947 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of InMode by 63.6% during the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock worth $20,502,000 after purchasing an additional 437,122 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of InMode by 3.4% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 900,831 shares of the healthcare company’s stock worth $19,467,000 after purchasing an additional 29,519 shares during the last quarter. Swedbank AB acquired a new position in InMode during the first quarter worth $17,634,000. Finally, Vanguard Group Inc. grew its holdings in InMode by 0.6% during the first quarter. Vanguard Group Inc. now owns 751,537 shares of the healthcare company’s stock worth $16,241,000 after acquiring an additional 4,387 shares during the period. Hedge funds and other institutional investors own 68.04% of the company’s stock.

Analysts Set New Price Targets

INMD has been the topic of several research reports. Barclays lowered their target price on InMode from $33.00 to $29.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Thursday, July 11th. Jefferies Financial Group downgraded InMode from a “buy” rating to a “hold” rating and dropped their target price for the company from $21.00 to $19.00 in a report on Tuesday, July 23rd. Finally, Canaccord Genuity Group dropped their target price on InMode from $21.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, July 12th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, InMode presently has an average rating of “Hold” and an average price target of $22.40.

InMode Price Performance

Shares of NASDAQ INMD opened at $15.50 on Wednesday. InMode Ltd. has a one year low of $15.18 and a one year high of $30.76. The business’s 50-day moving average price is $16.58 and its two-hundred day moving average price is $17.84. The company has a market capitalization of $1.30 billion, a P/E ratio of 7.35 and a beta of 2.17.

InMode (NASDAQ:INMD) last posted its quarterly earnings data on Thursday, August 1st. The healthcare company reported $0.34 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.04). InMode had a return on equity of 21.00% and a net margin of 35.81%. The business had revenue of $102.60 million for the quarter, compared to analyst estimates of $104.81 million. During the same period in the prior year, the firm posted $0.65 EPS. InMode’s revenue for the quarter was down 24.6% on a year-over-year basis. On average, equities analysts anticipate that InMode Ltd. will post 1.63 EPS for the current year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.